124 related articles for article (PubMed ID: 7529808)
41. Human complement regulatory proteins expressed on mouse A9 cells containing a human chromosome 1.
Seya T; Okada M; Hara T; Matsumoto M; Miyagawa S; Oshimura M
Immunology; 1991 Dec; 74(4):719-24. PubMed ID: 1723716
[TBL] [Abstract][Full Text] [Related]
42. Complement regulatory proteins and autoimmunity.
Kawano M
Arch Immunol Ther Exp (Warsz); 2000; 48(5):367-72. PubMed ID: 11140463
[TBL] [Abstract][Full Text] [Related]
43. Membrane-bound C4b interacts endogenously with complement receptor CR1 of human red cells.
Kinoshita T; Medof ME; Hong K; Nussenzweig V
J Exp Med; 1986 Nov; 164(5):1377-88. PubMed ID: 2430040
[TBL] [Abstract][Full Text] [Related]
44. Decay-accelerating factor (CD55) is expressed by neurons in response to chronic but not acute autoimmune central nervous system inflammation associated with complement activation.
van Beek J; van Meurs M; 't Hart BA; Brok HP; Neal JW; Chatagner A; Harris CL; Omidvar N; Morgan BP; Laman JD; Gasque P
J Immunol; 2005 Feb; 174(4):2353-65. PubMed ID: 15699172
[TBL] [Abstract][Full Text] [Related]
45. Enhanced expression of complement regulatory proteins on thyroid epithelial cells of Graves' disease.
Nakai H; Hirakawa S; Hayakawa N; Amano T; Ota Z
Acta Med Okayama; 1992 Oct; 46(5):323-30. PubMed ID: 1279944
[TBL] [Abstract][Full Text] [Related]
46. Low expression of erythrocyte complement receptor type 1 in chronic hepatitis C patients.
Kanto T; Hayashi N; Takehara T; Katayama K; Kato M; Akiyama M; Kasahara A; Fusamoto H; Kamada T
J Med Virol; 1996 Oct; 50(2):126-34. PubMed ID: 8915878
[TBL] [Abstract][Full Text] [Related]
47. Decay-accelerating factor (DAF) on the blood cell membranes in patients with paroxysmal nocturnal haemoglobinuria (PNH): measurement by enzyme-linked immunosorbent assay (ELISA).
Ninomiya H; Abe T; Shichishima T; Terasawa T; Fujita T
Br J Haematol; 1988 May; 69(1):81-7. PubMed ID: 2454648
[TBL] [Abstract][Full Text] [Related]
48. Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas.
Koretz K; Brüderlein S; Henne C; Möller P
Br J Cancer; 1992 Nov; 66(5):810-4. PubMed ID: 1384641
[TBL] [Abstract][Full Text] [Related]
49. Purification and characterization of IgG immunoconglutinins from patients with systemic lupus erythematosus: implications for a regulatory function.
Nilsson B; Ekdahl KN; Svarvare M; Bjelle A; Nilsson UR
Clin Exp Immunol; 1990 Nov; 82(2):262-7. PubMed ID: 2146995
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
Medof ME; Kinoshita T; Nussenzweig V
J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
[TBL] [Abstract][Full Text] [Related]
51. Low number of complement C3b/C4b receptors (CR1) on erythrocytes from patients with essential mixed cryoglobulinemia, systemic lupus erythematosus and rheumatoid arthritis: relationship with disease activity, anticardiolipin antibodies, complement activation and therapy.
Corvetta A; Pomponio G; Bencivenga R; Luchetti MM; Spycher M; Spaeth PJ; Danieli G
J Rheumatol; 1991 Jul; 18(7):1021-5. PubMed ID: 1833542
[TBL] [Abstract][Full Text] [Related]
52. Serum levels of C1q, C1r and C1s in normal and pathologic sera.
De Bracco MM; Manni JA
Arthritis Rheum; 1974; 17(2):121-8. PubMed ID: 4205506
[No Abstract] [Full Text] [Related]
53. Morphoea lesions are associated with aberrant expression of membrane cofactor protein and decay accelerating factor in vascular endothelium.
Venneker GT; Das PK; Naafs B; Tigges AJ; Bos JD; Asghar SS
Br J Dermatol; 1994 Aug; 131(2):237-42. PubMed ID: 7522514
[TBL] [Abstract][Full Text] [Related]
54. Heterogenous expression of decay accelerating factor and CD59/membrane attack complex inhibition factor on paroxysmal nocturnal haemoglobinuria (PNH) erythrocytes.
Shichishima T; Terasawa T; Hashimoto C; Ohto H; Uchida T; Maruyama Y
Br J Haematol; 1991 Aug; 78(4):545-50. PubMed ID: 1716957
[TBL] [Abstract][Full Text] [Related]
55. The change in C3b receptors on erythrocytes from patients with systemic lupus erythematosus.
Yoshida K; Yukiyama Y; Hirose S; Miyamoto T
Clin Exp Immunol; 1985 Jun; 60(3):613-21. PubMed ID: 3160514
[TBL] [Abstract][Full Text] [Related]
56. Family studies of erythrocyte complement receptor type 1 levels: reduced levels in patients with SLE are acquired, not inherited.
Walport MJ; Ross GD; Mackworth-Young C; Watson JV; Hogg N; Lachmann PJ
Clin Exp Immunol; 1985 Mar; 59(3):547-54. PubMed ID: 3987091
[TBL] [Abstract][Full Text] [Related]
57. Reduced complement receptor 1 (CR1, CD35) transcription in systemic lupus erythematosus.
Arora V; Verma J; Dutta R; Marwah V; Kumar A; Das N
Mol Immunol; 2004 Jun; 41(4):449-56. PubMed ID: 15163541
[TBL] [Abstract][Full Text] [Related]
58. [Complement regulatory proteins CR 1, MCP, DAF, and MACIF levels in patients with Behçet's disease].
Kure T; Kogure M
Nippon Ganka Gakkai Zasshi; 1996 May; 100(5):376-80. PubMed ID: 8651056
[TBL] [Abstract][Full Text] [Related]
59. Autoantibodies against complement receptor 1 (CD35) in SLE, liver cirrhosis and HIV-infected patients.
Sadallah S; Hess C; Trendelenburg M; Vedeler C; Lopez-Trascasa M; Schifferli JA
Clin Exp Immunol; 2003 Jan; 131(1):174-81. PubMed ID: 12519402
[TBL] [Abstract][Full Text] [Related]
60. Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus.
Wilson JG; Ratnoff WD; Schur PH; Fearon DT
Arthritis Rheum; 1986 Jun; 29(6):739-47. PubMed ID: 2941021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
